Pancreatic Cancer Research

ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Yi‐Ming Shyr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1914-0113; OpenAlex author ID A5007383914, A5109898985, A5110008000. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 2, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 paper · 2012: 1 paper, 1 trial · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 11

  1. Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2026.09.005↗
  2. Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience. Co-author DOI 10.1016/j.radonc.2025.111238↗
  3. Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma with robotic and open pancreatoduodenect… Co-author DOI 10.1007/s00464-021-08437-7↗
  4. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal a… Co-author DOI 10.1016/j.ejca.2022.01.030↗
  5. Effect of epidural analgesia on long-term outcomes after curative surgery for pancreatic cancer: A single-center cohort study in Taiwan. Co-author DOI 10.1097/jcma.0000000000000615↗
  6. Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. Co-author DOI 10.1080/2162402x.2018.1424612↗
  7. Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis. First author DOI 10.18632/oncotarget.13845↗
  8. Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. Co-author DOI 10.18632/oncotarget.10583↗
  9. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Co-author DOI 10.18632/oncotarget.4216↗
  10. Reappraisal of pancreatic adenocarcinoma undergoing pancreaticoduodenectomy. First author DOI 10.5754/hge10558↗
  11. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. Co-author DOI 10.1371/journal.pone.0020029↗

Trials 2

  1. Biomarkers Study in Pancreatic Cancer Principal investigator NCT01666184↗
  2. A Phase III Study of Pancreatic Cancer Principal investigator NCT00994721↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chung‐Pin Li · 5 shared papers, 2015–2026 · strength 0.72
  2. Yuan‐Hung Wu · 3 shared papers, 2022–2026 · strength 0.60
  3. Keng-Li Lan · 2 shared papers, 2026 · strength 0.49
  4. Nai‐Jung Chiang · 2 shared papers, 2026 · strength 0.49
  5. I‐Chun Lai · 2 shared papers, 2026 · strength 0.49
  6. Shin‐E Wang · 3 shared papers, 2016–2022 · strength 0.39
  7. I‐Wei Ho · 1 shared paper, 2026 · strength 0.26
  8. Hung-Yuan Yu · 1 shared paper, 2026 · strength 0.23
  9. Yu‐Wen Hu · 1 shared paper, 2026 · strength 0.23
  10. Minghuang Chen · 1 shared paper, 2026 · strength 0.23
  11. Bor‐Uei Shyr · 1 shared paper, 2022 · strength 0.22
  12. Kuan-Ju Lin · 1 shared paper, 2022 · strength 0.19
  13. Kuang-Yi Chang · 1 shared paper, 2022 · strength 0.19
  14. Yee Chao · 2 shared papers, 2015–2022 · strength 0.16
  15. Tsann‐Long Hwang · 1 shared paper, 2 shared trials, 2009–2012 · strength 0.14
  16. Shih‐Ming Hsu · 1 shared paper, 2022 · strength 0.11
  17. Long‐Sheng Lu · 1 shared paper, 2022 · strength 0.11
  18. Jeng-Fong Chiou · 1 shared paper, 2022 · strength 0.11
  19. Ruey-Kuen Hsieh · 1 shared trial, 2012 · strength 0.08
  20. Kee Voon Chua · 1 shared paper, 2018 · strength 0.08
  21. Tze‐Sing Huang · 1 shared paper, 2018 · strength 0.08
  22. Chia‐Chi Chen · 1 shared paper, 2018 · strength 0.08
  23. Chi-Shuan Fan · 1 shared paper, 2018 · strength 0.08
  24. Li‐Tzong Chen · 1 shared paper, 2018 · strength 0.08
  25. Chi–Che Hsieh · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.